Company Encyclopedia
View More
name
Formycon AG
FYB.DE
News
View More

Zydus and Formycon enter into an Exclusive Partnership for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab), in US and Canada | MRK Stock News

Zydus Lifesciences and Formycon AG have entered a strategic partnership for the exclusive licensing and supply of FYB206, a biosimilar of Keytruda®, in the USA and Canada. Formycon will develop and supply the product, while Zydus will handle commercialization. This collaboration marks Zydus' entry into the North American biosimilar market, aiming to make immunotherapy affordable and accessible. The BLA application will be submitted to the USFDA soon.

StockTitan·
DE
FYB
0.00%
US
MRK
+0.40%
StockTitan·
DE
FYB
0.00%
US
MRK
+0.40%

Formycon AG’s Strategic Partnerships and Biosimilar Advancements Drive Buy Rating

H.C. Wainwright analyst Yi Chen reiterated a Buy rating for Formycon AG, setting a €40.00 price target, citing strategic partnerships and biosimilar advancements. Key developments include a licensing deal with MS Pharma for FYB206 in the MENA region and collaboration with NTC s.r.l. for FYB203 in Italy. These moves, along with the technical proof of similarity for FYB208, support a positive outlook. Berenberg Bank also maintained a Buy rating with a €30.00 target.

Tip Ranks·
DE
FYB
0.00%
Tip Ranks·
DE
FYB
0.00%

04:15 ET Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the MENA Region

Formycon AG and MS Pharma have signed an exclusive licensing and supply agreement for the commercialization of Formycon's Keytruda® biosimilar candidate, FYB206, in the MENA region. The deal includes future technology transfer options and aims to improve access to cancer treatment. Formycon will receive upfront remuneration and share in gross profits, while MS Pharma will enhance treatment availability and support national healthcare strategies.

prnewswire·
DE
FYB
0.00%
prnewswire·
DE
FYB
0.00%

Formycon Says Co & MS Pharma Sign Exclusive Commercialization Partnership For Keytruda® Biosimilar Candidate FYB206 For MENA Region

Formycon AG :EQS-NEWS: FORMYCON AND MS PHARMA SIGN EXCLUSIVE COMMERCIALIZATION PARTNERSHIP FOR KEYTRUDA® BIOSIMILAR CANDIDATE FYB206 FOR THE MENA REGIONFORMYCON : WILL RECEIVE UPFRONT REMUNERATION & WILL BE ELIGIBLE FOR FURTHER PAYMENTS CONTINGENT ON ACHIEVEMENT OF CERTAIN MILESTONES

Reuters·
DE
FYB
0.00%
Reuters·
DE
FYB
0.00%

NTC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/Baiama® in Italy

Formycon AG and NTC have announced a partnership for the commercialization of Formycon's Eylea® biosimilar FYB203/Baiama® in Italy. Klinge Biopharma GmbH, the global rights holder, will receive royalties, while Formycon will manage the supply chain and receive service payments. The biosimilar, approved by FDA and EMA, offers a cost-effective treatment for retinal diseases.

EQS·
DE
FYB
0.00%
EQS·
DE
FYB
0.00%
© 2025 Longbridge｜Disclaimer